Gene,HGNC Symbol,Friendly Name,Entrez ID,Pathway,Therapy Type,Description,IO_target_URL
TNFRSF9 (4-1BB),TNFRSF9,4-1BB,3604,Cytokine-cytokine receptor interaction,T-cell targeted immunomodulator,"A co-stimulatory molecule highly expressed by T cells, as well as by other immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;4-1BB
TPBG (5T4),TPBG,5T4,7162,Wnt/beta-Catenin pathway,Targeted by Other Immuno-Oncology Therapy Type,5T4 is an antagonist of the Beta-Catenin pathway.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;5T4
ABCB5 (ABCB5),ABCB5,ABCB5,340273,ABC-family proteins mediated transport,Targeted by Other Immuno-Oncology Therapy Type,"A protein highly expressed by melanoma cell, and it is also in the family of ABC transporter and P-glycoprotein family.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ABCB5
ACPP (ACPP),ACPP,ACPP,55,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,A enzyme produced by the prostate and generally is elevated in men with prostate cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ACPP
DPP4 (ADABP),DPP4,ADABP,1803,Protein digestion and absorption,Other immunomodulator,A cell surface marker highly expressed in activated T cell.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ADABP
ADAM17 (ADAM17),ADAM17,ADAM17,6868,Metallopeptidase,Other immunomodulator,Belongs to metallopeptidase family and help the maturation of TNF.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ADAM17
ADAM9 (ADAM9),ADAM9,ADAM9,8754,Metallopeptidase,Other immunomodulator,Belongs to metallopeptidase family.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ADAM9
ADORA2A (ADORA2A),ADORA2A,ADORA2A,135,Adenosine receptor pathway,T-cell targeted immunomodulator,It is a popular target in immuno-oncology due to its function of immunosuppressive effects in tumor microenvironment.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ADORA2A
ADORA2B (ADORA2B),ADORA2B,ADORA2B,136,Adenosine receptor pathway,T-cell targeted immunomodulator,It is a popular target in immuno-oncology (not as prevalent as ADORA2A) due to its function of immunosuppressive effects in tumor microenvironment.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ADORA2B
MTDH (AEG1),MTDH,AEG1,92140,C-MYC Transcriptional Activation,Targeted by Other Immuno-Oncology Therapy Type,A oncogene highly expressed by many cancer cell.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;AEG1
AFP (AFP),AFP,AFP,174,Hippo signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,A protein highly expressed in human fetus.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;AFP
LALBA (Alpha-lactalbumin),LALBA,Alpha-lactalbumin,3906,Galactose metabolism,Targeted by Other Immuno-Oncology Therapy Type,This protein regulates the production of human milk.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Alpha-lactalbumin
AMHR2 (AMHR2),AMHR2,AMHR2,269,Cytokine-cytokine receptor interaction,Targeted by Other Immuno-Oncology Therapy Type,Hormone receptor involved in male sex differentiation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;AMHR2
ANGPT1 (ANG1),ANGPT1,ANG1,284,Angiogenesis,Other immunomodulator,"This protein is one type of angiopoietins, which induce apoptosis and formation of new vasculature.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ANG1
ANGPT2 (ANG2),ANGPT2,ANG2,285,Angiogenesis,Other immunomodulator,"This protein is one type of angiopoietins, which induce apoptosis and formation of new vasculature.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ANG2
AR (AR),AR,AR,367,Androgen receptor signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,The receptor of androgen hormone and it is highly expressed in certain types of prostate cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;AR
ARG1 (Arginase),ARG1,Arginase,383,Amino Acid metabolism,Other immunomodulator,"In tumor microenvironment, arginase degrades arginine into urea. Arginine is an important amino acid for immune cell growth, and depletion of it lead to immunosuppression.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Arginase
ASPH (ASPH),ASPH,ASPH,444,Ion Channel Transport,Targeted by Other Immuno-Oncology Therapy Type,Overexpression of ASPH associates with increase incidence of cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ASPH
SLC5A5 (ATRT),SLC5A5,ATRT,6528,Amino Acid metabolism,Targeted by Other Immuno-Oncology Therapy Type,This is a sodium-iodide transporter.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ATRT
AURKA (AURKA),AURKA,AURKA,6790,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,AURKA is a kinase and its dysregulation is common among many cancer types. Its high expression among cancers make it a target for cancer vaccine.,
AURKB (AURKB),AURKB,AURKB,9212,Regulation of Microtubule Cytoskeleton,Targeted by Other Immuno-Oncology Therapy Type,AURKB is a kinase and its dysregulation is common among many cancer types. Its high expression among cancers make it a target for cancer vaccine.,
AXL (AXL),AXL,AXL,558,Extracellular matrix induced cytoplasmic events,Other immunomodulator,AXL receptor transduce signal from extracellular matrix in to cytoplasm,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;AXL
CD276 (B7-H3),CD276,B7-H3,80381,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"Binds to CD28, CTLA-4, or ICOS to induce subsequent signaling events mainly in immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;B7-H3
VTCN1 (B7-H4),VTCN1,B7-H4,79679,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"Belongs to B7 family, which includes B7-H3. This molecule is reportedly a checkpoint molecule.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;B7-H4
DKFZp686O24166 (B7-H6),DKFZp686O24166,B7-H6,374383,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,Belongs to B7 family and binds to NKp30.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;B7-H6
TNFRSF13C (BAFF-R),TNFRSF13C,BAFF-R,115650,Cytokine-cytokine receptor interaction,Targeted by Other Immuno-Oncology Therapy Type,BAFF-R is member of TNF superfamily. It is highly expressed by certain lymphoma and is a target of cell therapy for this disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;BAFF-R
BARD1 (BARD1),BARD1,BARD1,580,DNA repair,Targeted by Other Immuno-Oncology Therapy Type,BARD1 binds with BRCA1 to form a complex that stabilizes the function of BRCA1,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;BARD1
BCL2 (BCL2),BCL2,BCL2,596,Apoptosis,Targeted by Other Immuno-Oncology Therapy Type,"BCL-2 is pro-apoptotic, which induces apoptosis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;BCL2
TNFRSF17 (BCMA),TNFRSF17,BCMA,608,Genotoxicity pathway,Targeted by Other Immuno-Oncology Therapy Type,BCMA is specifically expressed on matured B cells. It is also a very popular target for CAR-T cells for multiple myeloma.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;BCMA
CTNNB1 (Beta catenin),CTNNB1,Beta catenin,1499,Wnt/beta-Catenin pathway,Other immunomodulator,"Beta-Catenin is an important component of Wnt/Beta-Catenin pathway, which plays critical role in many biological functions and diseases.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Beta catenin
POU2AF1 (BOB-1),POU2AF1,BOB-1,5450,Antigen,Targeted by Other Immuno-Oncology Therapy Type,BOB-1 is suggested to be a good marker for B-cell malignancies. CAR-T cell therapies against this target are being developed.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;BOB-1
T (Brachyury),T,Brachyury,6862,Epithelial to Mesenchymal Transition,Targeted by Other Immuno-Oncology Therapy Type,"Brachyury is an important transcription factor that promotes epithelial-mesenchymal transition (EMT), and many cancer vaccines target this molecule.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Brachyury
HSP90B1 (BTE6-LX-8b),HSP90B1,BTE6-LX-8b,7184,Toll-like Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,Peptides derived from HSP90B1 are believed to be immunogenic in certain tumor environment and cancer vaccine are being developed based on those peptide sequences. Heat shock proteins are chaperon proteins that help other protein fold into the correct formation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;BTE6-LX-8b
HSP90B1 (BTE6-X-15-7),HSP90B1,BTE6-X-15-7,7184,Toll-like Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,Peptides derived from HSP90B1 are believed to be immunogenic in certain tumor environment and cancer vaccine are being developed based on those peptide sequences. Heat shock proteins are chaperon proteins that help other protein fold into the correct formation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;BTE6-X-15-7
KIT (c-KIT),KIT,c-KIT,3815,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"c-KIT is a cytokine receptor expressed on cell surface, and it plays role in many types of cancer and is a popular cancer target.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;c-KIT
CA9 (CA9),CA9,CA9,768,Vitamin D Receptor Pathway,Targeted by Other Immuno-Oncology Therapy Type,Carbonic anhydrases(CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. It is overexpressed in certain solid tumors and it is a target for cancer vaccines.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CA9
CNR2 (CB2),CNR2,CB2,1269,Cannabinoid receptor signaling,Other immunomodulator,"CB2 is responsible for the cell proliferation of certain types of cancer cells. Small molecule that activate CB2 is reportedly to elevate the expression of MHC I on cancer cells, and this leads to enhanced immune response to the cancer cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CB2
CBLB (CBLB),CBLB,CBLB,868,T-Cell antigen Receptor (TCR) Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"CBL-B functions as a negative regulator of T-cell activation. CBL-B expression in T cells causes ligand-induced T cell receptor down-modulation, controlling the activation degree of T cells during antigen presentation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CBLB
CCL20 (CCL20),CCL20,CCL20,6364,Interleukin-10 signaling,Targeted by Other Immuno-Oncology Therapy Type,CCL20 is a strong chemokine that attracts lymphocytes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CCL20
CCL3 (CCL3),CCL3,CCL3,6348,Chemokine signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"CCL3 is a chemokine and it binds to CCR1, CCR4, and CCR5.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CCL3
CCNB1 (CCNB1),CCNB1,CCNB1,891,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,"CCNB1 plays an important role in cell mitosis, especially during the G2 to M phase transition. It is highly expressed in certain cancers and is being pursued as a target for cancer vaccines.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CCNB1
CCR1 (CCR1),CCR1,CCR1,1230,Chemokine signaling pathway,Other immunomodulator,"CCR1 is a chemokine receptor that binds with CCL3, CCL5, CCL 7, and CCL23.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCR1
CCR2 (CCR2),CCR2,CCR2,729230,Chemokine signaling pathway,Other immunomodulator,CCR2 is a chemokine receptor that binds with CCL2. CCR2 is important for monocyte migration into tumor or other inflammatory tissues. It is also important for monocytes to migrate out from bone marrow.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CCR2
CCR4 (CCR4),CCR4,CCR4,1233,Chemokine signaling pathway,Other immunomodulator,"CCR4 is a chemokine receptor that binds with CCL2, CCL4, CCL7, CCL 17, and CCL22. It helps the migration of leukocytes.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CCR4
CCR7 (CCR7),CCR7,CCR7,1236,Chemokine signaling pathway,Other immunomodulator,"CCR7 is a chemokine receptor that binds with CCL19 and CCL 21. CCR7 is highly expressed by certain types of dendritic cells, which play pivotal role in facilitate the anti-tumor adaptive immunity in cancer. CCR7 also plays role in T cell migration.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCR7
CCR9 (CCR9),CCR9,CCR9,10803,Chemokine signaling pathway,Other immunomodulator,CCR9 is a chemokine receptor that binds to CCL25. CCR9 may play role in T cell migration in intestine and colon.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCR9
ITGAM (CD11b),ITGAM,CD11b,3684,Interleukin-4 and Interleukin-13 signaling,Other immunomodulator,"CD11b is a surface marker for leukocytes in the innate immune system, including monocytes, macrophages, granulocytes, and NK cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD11b
IL3RA (CD123),IL3RA,CD123,3563,IL-3 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"CD123 is the receptor for IL-3, an important cytokine for the immune system. CD123 is highly expressed in acute myeloid leukemia, and is being pursued as a target for cancer cell therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD123
ANPEP (CD13),ANPEP,CD13,290,Glutathione metabolism,Targeted by Other Immuno-Oncology Therapy Type,CD13 defects is associated with certain types of leukemia and lymphoma. CD13 is being pursued by cancer cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD13
PROM1 (CD133),PROM1,CD133,8842,Extracellular vesicle-mediated signaling,Targeted by Other Immuno-Oncology Therapy Type,CD133 is highly expressed in certain subtypes of melanoma cells. It is being pursed by several cancer vaccines as the target.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD133
FLT3 (FLT3),FLT3,FLT3,2322,Leukocyte development,Other immunomodulator,FLT3 is the receptor for FLT-3L. This pathway is important for normal hematopoietic stem cell development. It is also critical for B and T cell development. CD135 is a target for certain leukemia.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;FLT3
SDC1 (CD138),SDC1,CD138,6382,Cell adhesion molecules (CAMs),Targeted by Other Immuno-Oncology Therapy Type,CD138 is highly expressed in different tumor types and specifically on multiple myeloma cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD138
BSG (CD147),BSG,CD147,682,Matrix Metalloproteinases,Targeted by Other Immuno-Oncology Therapy Type,CD147 is highly expressed in certain immune cells and endothelial cells. CD147 is being pursued by cancer vaccines as a target.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD147
PVR (CD155),PVR,CD155,5817,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,CD155 normally involves in the adhesion between epithelial cells and also involves in the poliovirus infection in primates.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD155
FCGR3A (CD16),FCGR3A,CD16,2214,Complement system,Other immunomodulator,"CD16 has two isoforms, CD16a and CD16b. They are expressed in a wide range of immune cells and play important roles in phagocytosis and other key immune responses.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD16
CD160 (CD160),CD160,CD160,11126,Adaptive Immune System,Other immunomodulator,CD160's expression is strictly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. This molecule is a target for certain types of leukemia.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD160
FCGR3A (CD16a),FCGR3A,CD16a,2214,Complement system,Other immunomodulator,"CD16a is one of the two isoforms of CD16. CD16a is expressed on mast cells, macrophages, and natural killer cells as a transmembrane receptor.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD16a
L1CAM (CD171),L1CAM,CD171,3897,Cell adhesion molecules (CAMs),Targeted by Other Immuno-Oncology Therapy Type,CD171 is highly expressed in many types of cancer and its high expression is associated with poor prognosis.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD171
FUT3 (CD174),FUT3,CD174,2525,Glycosphingolipid biosynthesis - lacto and neolacto series,Targeted by Other Immuno-Oncology Therapy Type,CD174 is an enzyme encoded by human gene FUT3. It is highly expressed by certain types of blood malignancies and this molecule is a target for cancer cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD174
CD19 (CD19),CD19,CD19,930,B Cell Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,CD19 is expressed by B cells during all phases of their development. CD19 is an ideal target for cell therapy or monoclonal antibodies that are used for treating B-cell cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD19
MS4A1 (CD20),MS4A1,CD20,931,Hematopoietic cell lineage,Targeted by Other Immuno-Oncology Therapy Type,CD20 is expressed by B cells during all phases of their development except for the first and the last phases. CD20 is an ideal target for cell therapy or monoclonal antibodies that are used for treating B-cell cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD20
CD200 (CD200),CD200,CD200,4345,Macrophage activation,Other immunomodulator,CD200 is expressed in myeloid cells such as macrophages. It is reported that the activation of CD200 may inhibit the activation of macrophages.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD200
CR2 (CD21),CR2,CD21,1380,Complement system,Other immunomodulator,"CD21 binds to iC3b, a key molecule in the complement system of the immune system.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD21
CD22 (CD22),CD22,CD22,933,B Cell Receptor Signaling Pathway,Other immunomodulator,CD22 functions as an inhibitory receptor forcell receptor (BCR) signaling. CD22 is also an important target for B-cell malignancies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD22
IL2RA (IL2RA),IL2RA,IL2RA,3559,Inflammatory Response Pathway,T-cell targeted immunomodulator,"CD25 is the alpha chain of IL-2 receptor. Together with the beta chain, CD25 form the functional IL-2 receptor. The receptor binds to IL-2 and induce intracellular signaling that promote T cell proliferation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL2RA
TNFRSF13B (CD267),TNFRSF13B,CD267,23495,Cytokine-cytokine receptor interaction,Targeted by Other Immuno-Oncology Therapy Type,"CD267 is the receptor for ligands BAFF and APRIL. Activation of CD267 leads to the activation of NF-AT, NFkappaB, and AP-1.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD267
CD27 (CD27),CD27,CD27,939,T cell activation,T-cell targeted immunomodulator,CD27 is a co-stimulatory molecule of many immune cells. Activation of CD27 by its ligand CD70 leads to sustained T cell activation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD27
CD28 (CD28),CD28,CD28,940,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CD28 is a critical co-stimulatory molecule for T cell activation. Its binding ligands are CD80 and CD86. CD28 activation is an essential component for many cancer immunotherapies, especially the CAR-T therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD28
ITGB1 (CD29),ITGB1,CD29,3688,Cell adhesion molecules (CAMs),Other immunomodulator,CD29 is an important molecule for cell adhesion. Activation of CD29 also increase the migration of leukocytes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD29
CD3D (CD3D),CD3D,CD3D,915,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CD3 is the major component of TCR, and its intracellular signaling domain triggers cascades of intracellular events that control T cell activation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD3
CD3E (CD3E),CD3E,CD3E,916,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CD3 is the major component of TCR, and its intracellular signaling domain triggers cascades of intracellular events that control T cell activation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD3E
CD3G (CD3G),CD3G,CD3G,917,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CD3 is the major component of TCR, and its intracellular signaling domain triggers cascades of intracellular events that control T cell activation.",
TNFRSF8 (CD30),TNFRSF8,CD30,943,Cytokine-cytokine receptor interaction,Targeted by Other Immuno-Oncology Therapy Type,CD30 is highly expressed by certain types of lymphoma and is being pursed as a target for those cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD30
FCGR2A (FCGR2A),FCGR2A,FCGR2A,2212,B Cell Receptor Signaling Pathway,Other immunomodulator,CD32 is part of the B-cell co-receptors.,
FCGR2B (FCGR2B),FCGR2B,FCGR2B,2213,B Cell Receptor Signaling Pathway,Other immunomodulator,CD32 is part of the B-cell co-receptors.,
CD33 (CD33),CD33,CD33,945,Hematopoietic cell lineage,Targeted by Other Immuno-Oncology Therapy Type,CD33 is generally expressed in myeloid cells. CD33 is a target for leukemia.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD33
CD38 (CD38),CD38,CD38,952,Hematopoietic cell lineage,Targeted by Other Immuno-Oncology Therapy Type,"CD38 is highly expressed in many types of immune cells. CD38 also functions in cell adhesion, signal transduction and calcium signaling.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD38
ENTPD1 (CD39),ENTPD1,CD39,953,Adenosine receptor pathway,Other immunomodulator,CD39 is the enzyme involved in the pathway that hydrolyses extracellular ATP and leads to the generation of immunosuppressive adenosine. ATP promotes immune cell-mediated killing of cancer cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD39
CD3E (CD3E),CD3E,CD3E,916,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CD3E is part of the CD3, which is the major component of T-cell receptor complex. TCR is the key molecule for T cell activation and it binds to MHC I or II molecules.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD3E
CD4 (CD4),CD4,CD4,920,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,CD4 is an essential component of TCR complex. CD4 guides the TCR complex to binds with MHCII molecule from antigen presenting cells.,
CD40 (CD40),CD40,CD40,958,Cytokine-cytokine receptor interaction,Other immunomodulator,"CD40 is a receptor and it binds to ligand CD154. Activation of CD40 by its ligand activates the immune cells, most of which are T helper cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD40
CD44 (CD44),CD44,CD44,960,Hematopoietic cell lineage,Targeted by Other Immuno-Oncology Therapy Type,CD44 is marker for effector-memory T cell. It is also widely expressed in wide range of immune cells. It is highly expressed in certain types of T-cell leukemia and therefore an ideal target for cancer cell therapy.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD44
CD46 (CD46),CD46,CD46,4179,Complement system,Other immunomodulator,CD46 is a type I membrane protein and is a regulatory component of the complement system of the immune system.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD46
CD47 (CD47),CD47,CD47,961,Innate Immune System,Other immunomodulator,"CD47 is the receptor of SIRP, and the activation of CD47 by the binding of SIRP leads to the inhibition of phagocytosis process. This pathway is sometime referred to as ""don't eat me"" signal.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD47
ITGAV (CD51),ITGAV,CD51,3685,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"CD51 is the essential subunit of integrins, which have different subtypes. CD51 is highly expressed in tumors such as colorectal cancer and prostate cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD51
CD52 (CD52),CD52,CD52,1043,Protein metabolism,T-cell targeted immunomodulator,CD52 is expressed by the mature lymphocytes but not their stem cell counterparts. It is a target for chronic lympholytic leukemia.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD52
ICAM1 (CD54),ICAM1,CD54,3383,Cell adhesion molecules (CAMs),Targeted by Other Immuno-Oncology Therapy Type,"CD54 is expressed on low level on leukocytes and endothelial cells, but its express is highly elevated when the cell are activated by infection or inflammation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD54
NCAM1 (CD56),NCAM1,CD56,4684,Cell adhesion molecules (CAMs),Targeted by Other Immuno-Oncology Therapy Type,"CD56 is highly expressed in NK cells, and its high expression is also associated with certain types of tumors.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD56
CD7 (CD7),CD7,CD7,924,Hematopoietic cell lineage,Targeted by Other Immuno-Oncology Therapy Type,CD7 is highly expressed in certain types of T cell and it is a target for cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD7
CD70 (CD70),CD70,CD70,970,Cytokine-cytokine receptor interaction,T-cell targeted immunomodulator,"CD70 is the ligand for CD27. CD70 activates CD27, which leads to the long-term maintenance of T cell immunity.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD70
NT5E (CD73),NT5E,CD73,4907,NAD+ metabolism,Other immunomodulator,"CD73 is an enzyme and it metabolizes AMP to produce adenosine, an immunosuppressive molecule that binds to adenosine 2A receptor.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD73
CD80 (CD80),CD80,CD80,941,Toll-like Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"CD80 is a ligand for CD28 and CTLA-4, and it is expressed on antigen-presenting cells such as B-cells, macrophages, monocytes, and dendritic cells. The binding of CD80 to CD28 leads to T cell proliferation and serves as the essential co-stimulatory signal, or the secondary signal for T cell activation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD80
C5AR1 (CD88),C5AR1,CD88,728,Complement system,Targeted by Other Immuno-Oncology Therapy Type,"CD88 is the complement system receptor, whose binding to ligand C5a leads to strong inflammatory response.",
CDH3 (CDH3),CDH3,CDH3,1001,Cell adhesion molecules (CAMs),Targeted by Other Immuno-Oncology Therapy Type,CDH3 is a calcium-dependent cell-cell adhesion glycoprotein.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CDH3
MST1R (CDw136),MST1R,CDw136,4486,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Other immunomodulator,CDw136 has associative function with c-MET. CDw136 is shown to be interacted with Grb2,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CDw136
CEACAM1 (CEACAM1),CEACAM1,CEACAM1,634,Innate Immune System,Other immunomodulator,"CEACAM1 is a member of CEA family and it is normally only expressed in cells at embryonic stage. However, certain cancers express this molecule at mature stages and therefore a target for cancer therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CEACAM1
CEACAM5 (CEACAM5),CEACAM5,CEACAM5,1048,Innate Immune System,Other immunomodulator,"CEACAM5 is a member of CEA family and it is normally only expressed in cells at embryonic stage. However, certain cancers express this molecule at mature stages and therefore a target for cancer therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CEACAM5
CEACAM6 (CEACAM6),CEACAM6,CEACAM6,4680,Innate Immune System,Other immunomodulator,"CEACAM6 is a member of CEA family and it is normally only expressed in cells at embryonic stage. However, certain cancers express this molecule at mature stages and therefore a target for cancer therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CEACAM6
CLDN18 (Claudin 18),CLDN18,Claudin 18,51208,Tight junction,Targeted by Other Immuno-Oncology Therapy Type,"Claudin-18 belongs to claudin family, and it contributes to the formation of the tight junction strands in epithelial cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Claudin 18
CLDN6 (Claudin 6),CLDN6,Claudin 6,9074,Tight junction,Targeted by Other Immuno-Oncology Therapy Type,"Claudin-6 belongs to claudin family, and it contributes to the formation of the tight junction strands in epithelial cells.",
CLEC12A (CLEC12A),CLEC12A,CLEC12A,160364,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,CLEC12A is highly expressed in acute myeloid leukemia cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CLEC12A
MET (cMET),MET,cMET,4233,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"C-MET is a tyrosine kinase receptor, and its natural ligands are HGF and its spliced forms. High expression of c-MET associates with poor prognosis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;cMET
PTGS1 (COX),PTGS1,COX,5742,Cox pathway,Other immunomodulator,"COX is an enzyme that produces prostanoids, which leads to inflammation and pain. Inhibition of COX relieve inflammation and pain.",
PTGS2 (COX-2),PTGS2,COX-2,5743,Interleukin-10 signaling,Other immunomodulator,"COX-2 is one type of COX. COX is an enzyme that produces prostanoids, which leads to inflammation and pain. Inhibition of COX relieve inflammation and pain.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;COX-2
CPEB4 (CPEG4),CPEB4,CPEG4,80315,Glucocorticoid Receptor Pathway,Other immunomodulator,CPEG4 is highly expressed in cancer cells and therefore a target for cancer therapies such as oncolytic virus.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CPEG4
CRLF2 (CRLF2),CRLF2,CRLF2,64109,JAK/STAT Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"CRLF2 can forms a complex with TSLP and IL7R, and its engagement leads to the activation of JAK/STAT pathway as well as the cell proliferation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CRLF2
SLAMF7 (CS1),SLAMF7,CS1,57823,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,"CS1 is highly expressed in multiple myeloma cells, and it is a target for cancer cell therapies and monoclonal antibodies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CS1
CSF1 (CSF1),CSF1,CSF1,1435,Differention of Dendritic Cells,Other immunomodulator,CSF1 differentiates hematopoietic stem cells into the macrophages or other related cell types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CSF1
CSF1R (CSF1R),CSF1R,CSF1R,1436,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Other immunomodulator,"CSF1R is the receptor of CSF1, and the activation of CSF1R leads to the differentiation to macrophages and the survival of the cells too. CSF1R is highly expressed in tumor-associated macrophages, which take immunosuppressive role in tumors. Therefore, CSF1R is a popular target in immuno-oncology.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CSF1R
CTCFL (CTCFL),CTCFL,CTCFL,140690,Antigen,Targeted by Other Immuno-Oncology Therapy Type,CTCFL is highly expressed in certain tumor cells and therefore is a target for cancer vaccines that are based on peptides derived from this protein.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CTCFL
CTLA4 (CTLA-4),CTLA4,CTLA-4,1493,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"CTLA-4 binds to CD80 or CD88 at much higher affinity than these two molecules binding to CD28. CTLA-4 therefore hijack the ligands from CD28, whose activation is essential for T cell activation and proliferation. CTLA-4 is a checkpoint molecule of T cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CTLA-4
CX3CR1 (CX3CR1),CX3CR1,CX3CR1,1524,Chemokine signaling pathway,Other immunomodulator,CX3CR1 is the receptor for CX3CL1. CX3CR1 involves in the adhesion and migration of leukocytes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CX3CR1
CXCL1 (CXCL1),CXCL1,CXCL1,2919,Cytokine-cytokine receptor interaction,Other immunomodulator,"CXCL1 binds to CXCR2. CXCL is expressed by macrophages, neutrophils, and epithelial cells. It is also involved in renal cell carcinoma cell proliferation and therefore a target for this cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CXCL1
CXCL12 (CXCL12),CXCL12,CXCL12,6387,Chemokine signaling pathway,Other immunomodulator,"CXCL12 is expressed in wide range of tissues, and it binds to CXCR4 and CXCR7. CXCL12 is a strong chemokine and its binding to CXCR4 leads to increased metastasis for certain tumor cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CXCL12
PPBP (CXCL7),PPBP,CXCL7,5473,Chemokine signaling pathway,Other immunomodulator,CXCL7 is involved in tumor migration and proliferation. Neutralization of this cytokine may prevent tumor growth.,
CXCR1 (CXCR1),CXCR1,CXCR1,3577,Chemokine signaling pathway,Other immunomodulator,"CXCR1 is the receptor for IL-8, and its activation is important for neutrophil chemotaxis and activation. CXCR1 is highly expressed in certain malignant melanoma cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CXCR1
CXCR2 (CXCR2),CXCR2,CXCR2,3579,Chemokine signaling pathway,Other immunomodulator,"CXCR1 is the receptor for IL-8, and its activation is important for neutrophil chemotaxis and activation. CXCR2 also binds to CXCL1, CXCL2, CXCL3, and CXCL5.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CXCR2
CXCR4 (CXCR4),CXCR4,CXCR4,7852,Chemokine signaling pathway,Other immunomodulator,"CXCR4 binds to CXCL12, which is expressed in wide range of tissues. Blocking of CXCR4 leads to the release of hematopoietic stem cells release into the blood. Drugs antagonizing CXCR4 is being used to increase the blood levels of stem cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CXCR4
CXCR5 (CXCR5),CXCR5,CXCR5,643,Chemokine signaling pathway,Other immunomodulator,"CXCR5 is the receptor of CXCL13, and its activation leads to the T cell migration into the B cell zone in the lymph nodes. Certain cancer cells rely on the signal from CXCR5 to proliferate and inhibition of this pathway prevent cancer growth.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CXCR5
CXCR7 (CXCR7),CXCR7,CXCR7,57007,Chemokine signaling pathway,Other immunomodulator,CXCR7 is the receptor for chemokines CXCL11 and CXCL12.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CXCR7
TYMS (Cytosine deaminase),TYMS,Cytosine deaminase,7298,One carbon metabolism and related pathways,Targeted by Other Immuno-Oncology Therapy Type,"Cytosine deaminase that converts the prodrug (5 FC), co-administered along with these cells to the active cytotoxic agent (5 FU). This molecule is encoded by the stem cell therapy which migrate into tumor bed and convert pro-drug into chemotherapeutic agent.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Cytosine deaminase
DCK (DCK),DCK,DCK,1633,Pyrimidine metabolism,Targeted by Other Immuno-Oncology Therapy Type,DCK is being utilized to convert gemcitabine prodrug to cytotoxic cancer therapy. DCK is being incorporated into oncolytic viruses that infect cancer cells and produce DCK to produce cytotoxic drugs in local tumor microenvironment.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;DCK
EP300 (E1A),EP300,E1A,2033,Cell Cycle,T-cell targeted immunomodulator,"EP300 functions as histone acetyltransferase that regulates transcription of genes via chromatin remodeling. This enzyme plays an essential role in regulating cell growth and division, prompting cells to mature and assume specialized functions (differentiate), and preventing the growth of cancerous tumors.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;E1A
EGF (EGF),EGF,EGF,1950,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"EGF is the ligand for EGFR. The binding of EGF to EGFR leads to the activation of this tyrosine kinase receptor pathway, leading to cell proliferation and growth.",
EGFR (EGFR),EGFR,EGFR,1956,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"EGFR is the receptor for EGF. The binding of EGF to EGFR leads to the activation of this tyrosine kinase receptor pathway, leading to cell proliferation and growth.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;EGFR
CLEC14A (EGFR5),CLEC14A,EGFR5,161198,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,EGFR5 is highly expressed in tumor vasculature and is a target for cancer cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;EGFR5
EGFR (EGFRvIII),EGFR,EGFRvIII,1956,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,EGFRvIII is a translational variant of EGFR. It is highly expressed in glioblastoma and a few other tumors. EGFRvIII is an important target for cancer cell therapies against glioblastoma.,
EIF2AK3 (EIF2AK3),EIF2AK3,EIF2AK3,9451,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"EIF2AK3 phosphorylates EIF2, and it is highly expressed in certain tumor cells. It is a target for cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;EIF2AK3
ELAVL4 (ELVAL4),ELAVL4,ELVAL4,1996,Antigen,Targeted by Other Immuno-Oncology Therapy Type,ELVAL4 is a RNA-binding protein. It is highly expressed in certain tumor cells and is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ELVAL4
EPCAM (EPCAM),EPCAM,EPCAM,4072,Antigen,Targeted by Other Immuno-Oncology Therapy Type,EPCAM is membrane protein and is highly expressed in certain types of tumors. It is a target for cancer vaccines and monoclonal antibodies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;EPCAM
EPHA2 (EPHA2),EPHA2,EPHA2,1969,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,EPHA2 is highly expressed in certain cancer types and is a target for cancer cell therapies and CD3-targeted bispecific antibodies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;EPHA2
EPS8 (EPS8),EPS8,EPS8,2059,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,EPSH8 is highly expressed in certain blood cancers and is a target for CAR-T therapy.,
ERG (ERG),ERG,ERG,2078,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,ERG is highly expressed in certain cancer types and is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ERG
FAIM3 (FAIM-3),FAIM3,FAIM-3,9214,MAPK Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,FAIM-3 is highly expressed by certain cancer types and is a target for cancer cell therapy.,
FAP (FAP),FAP,FAP,2191,Antigen,Targeted by Other Immuno-Oncology Therapy Type,FAP is highly expressed in human carcinomas. It is a target for cancer vaccines and oncolytic viruses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;FAP
FGF2 (FGF2),FGF2,FGF2,2247,MAPK signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"FGF2 is the ligand for FGFR, and the association of the 2 molecules activates FGFR, which leads to cell proliferation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;FGF2
FN1 (FN1),FN1,FN1,2335,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"FN1 is a component of extracellular matrix and it binds to integrins from the cell. FN1 plays an important role in cell adhesion, growth, migration, and differentiation. Due to its high expression in cancer, FN1 is a target for cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;FN1
FOLH1 (PSMA),FOLH1,PSMA,2346,Amino Acid metabolism,Targeted by Other Immuno-Oncology Therapy Type,PSMA is an enzyme that is highly expressed in human prostate cancer. PSMA is a popular target for prostate cancer by various cancer therapy types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PSMA
FOLR1 (FOLR1),FOLR1,FOLR1,2348,Folate Metabolism,Targeted by Other Immuno-Oncology Therapy Type,FOLR1 is the receptor for folic acid. Many cancers highly express FLOR1 and it is a target for various cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;FOLR1
FOLR2 (FOLR2),FOLR2,FOLR2,2350,Folate Metabolism,Targeted by Other Immuno-Oncology Therapy Type,FOLR2 belongs to the folic acid receptor family. It has high affinity to folic acid and is highly expressed in many cancer types.,
FOXM1 (FOXM1),FOXM1,FOXM1,2305,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways,Targeted by Other Immuno-Oncology Therapy Type,"FOXM1 plays important role in cell cycle. Its upregulation was found in the majority of cancer types. Due to its high expression in cancer, it is a target for cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;FOXM1
FSHR (FSHR),FSHR,FSHR,2492,GPCRs,Targeted by Other Immuno-Oncology Therapy Type,"FSHR is highly expressed in ovary, testis, and uterus. It is a target for cancer cell therapy against ovarian cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;FSHR
LGALS1 (Galectin-1),LGALS1,Galectin-1,3956,Differention of Dendritic Cells,Other immunomodulator,Galectin-1 induces the differentiation of dendritic cells towards a phenotype that educate the T cells to take an immunosuppressive phenotype. It is secreted by tumor cells.,
GAST (Gastrin),GAST,Gastrin,2520,MAPK signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,Gastrin is a peptide hormone that induces the secretion of gastric acid (HCI). It is also highly expressed in gastric cancer and therefore a target for cancer vaccines for those cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Gastrin
CSF3R (GCSFR),CSF3R,GCSFR,1441,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Other immunomodulator,GCSFR is the receptor for GCSF. Engagement of GCSFR activates the downstream pathway that includes STAT and ERK1/2.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;GCSFR
LGALS3 (Galectin-3),LGALS3,Galectin-3,3958,Innate Immune System,Other immunomodulator,"Galectin-3 plays important role in cell-cell adhesion, cell-matrix interaction, and macrophage activation. It is highly expressed in many types of cancer and is a target for various cancer therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LGALS3
LGALS9 (Galectin-9),LGALS9,Galectin-9,3965,Innate Immune System,Other immunomodulator,"Galectin-9 is highly expressed in many blood malignancies and solid tumors, and therefore a target for therapies against this target.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LGALS9
TNFRSF18 (GITR),TNFRSF18,GITR,8784,Development of regulatory T lymphocytes (Tregs),T-cell targeted immunomodulator,"GITR expression is elevated when T-cell is activated, and it is regarded as co-stimulatory molecule for T cells. It is a target for therapies to enhance T cell's functionality against tumors.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;GITR
CSF2 (GMCSF),CSF2,GMCSF,1437,Cytokine-cytokine receptor interaction,Other immunomodulator,GMCSF is a cytokine and it induces the stem cells to produce granulocytes and monocytes. It is used to help the recovery of white blood cells after chemotherapy.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;GMCSF
CSF2RA (GMCSFR),CSF2RA,GMCSFR,1438,Cytokine-cytokine receptor interaction,Other immunomodulator,"GMCSFR is the receptor for GMCSF, and activation of it leads to the production of white blood cell.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;GMCSFR
GNRHR (GNRHR),GNRHR,GNRHR,2798,GPCRs,Targeted by Other Immuno-Oncology Therapy Type,"The GnRHR is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate. Due to its high expression in cancer of these organs, it is a target of cancer cell therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GNRHR
GOLM1 (GP73),GOLM1,GP73,51280,Antigen,Targeted by Other Immuno-Oncology Therapy Type,GP73 is over-expressed in prostate cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GP73
HSP90B1 (HSP90B1),HSP90B1,HSP90B1,7184,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,Gp96 is a chaperon protein that help the correct formation of proteins synthesized in cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;HSP90B1
GPA33 (gpA33),GPA33,gpA33,10223,Antigen,Targeted by Other Immuno-Oncology Therapy Type,A cell membrane protein highly expressed by colon cancer cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;gpA33
GPC3 (GPC3),GPC3,GPC3,2719,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"GPC3 is over expressed in liver cancer, ovarian cancer, and breast cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;GPC3
NR3C1 (GR),NR3C1,GR,2908,Glucocorticoid Receptor Pathway,Other immunomodulator,The binding of glucocorticoids to GR leads to the expression of genes that lead to anti-inflammatory function. Antagonist of GR may reduce the immunosuppressive function of GR.,
H3F3A (H3.3K27M),H3F3A,H3.3K27M,3020,Histone Modifications,Targeted by Other Immuno-Oncology Therapy Type,H3.3K27M is mutant form of histone protein H3.3 with a point mutation of K to M at amino acid 27. It is suggested to be a good target for cancer vaccine as this point mutation is prevalent in certain types of pediatric glioma.,
HDAC1 (HDAC1),HDAC1,HDAC1,3065,Cell Cycle,Other immunomodulator,HDAC1 removes the acetylation of histones and therefore regulate the gene expression. It is reported that HDAC1 inhibitors may reduce the immunosuppressive phenotypes of certain immune cells.,
ERBB2 (HER2),ERBB2,HER2,2064,ErbB Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,Amplification of HER2 is a hallmark of HER2+ breast cancer. HER2 is also over expressed in many other cancer types and therefore an attractive target.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HER2
ERBB3 (HER3),ERBB3,HER3,2065,ErbB Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"HER3 is a tyrosine kinase receptor. Activation of HER3 leads to the activation of PI3K/Akt pathway. Due to its high expression in certain cancers, it is a target for cancer vaccines.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HER3
C7orf68 (HILPDA),C7orf68,HILPDA,29923,Vitamin D Receptor Pathway,Targeted by Other Immuno-Oncology Therapy Type,HILPDA is over expressed in certain tumor due to the hypoxia. It is being pursued as a cancer vaccine target.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HILPDA
HLA-A (HLA-A2),HLA-A,HLA-A2,3105,Proteasome Degradation,Targeted by Other Immuno-Oncology Therapy Type,HLA-A2 is a serotype of HLA-A.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HLA-A2
CSPG4 (HMW-MAA),CSPG4,HMW-MAA,1464,Antigen,Targeted by Other Immuno-Oncology Therapy Type,HMW-MAA is over expressed in melanoma cells and a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HMW-MAA
SLC17A5 (HP59),SLC17A5,HP59,26503,Lysosome,Targeted by Other Immuno-Oncology Therapy Type,HP59 is over expressed in tumor vasculature. It is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HP59
HSPH1 (HSP105),HSPH1,HSP105,10808,Cellular response to heat stress,Targeted by Other Immuno-Oncology Therapy Type,HSP105 is over expressed in colorectal cancer and a target for cancer vaccines for this cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HSP105
HSPA1A (HSP70),HSPA1A,HSP70,3303,MAPK Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,HSP70 is over expressed in human melanoma and non-small cell lung cancer. It is a caner vaccine target for those cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HSP70
TNFRSF14 (HVEM),TNFRSF14,HVEM,8764,Cytokine-cytokine receptor interaction,T-cell targeted immunomodulator,HVEM is a cell membrane receptor and it is used by HSV to enter infected cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;HVEM
ICOS (ICOS),ICOS,ICOS,29851,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,ICOS is a CD28 family member and works as a co-stimulatory molecule for T cells. It may preferentially activate Th2 cells. It is a popular target for T cells in immuno-oncology.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ICOS
IDH1 (IDH1),IDH1,IDH1,3417,Amino Acid metabolism,Targeted by Other Immuno-Oncology Therapy Type,"IDH1 is a an enzyme, whose product plays important role for DNA modification and therefore gene expression. IDH1 mutation is associated with poor prognosis of certain cancers, especially glioblastoma. Recent studies suggest IDH1 modulating drugs may also affect immune cells' function against cancer growth.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IDH1
IDO1 (IDO),IDO1,IDO,3620,Tryptophan metabolism,T-cell targeted immunomodulator,"IDO (encoded by IDO1 gene) is one the three enzymes that catalyze the first and rate-limiting step of in the kynurenine pathway. Kynurenine is a immunosuppressive molecule that binds to its receptor and induce immunosuppressive function on immune cells, especially T cell. Inhibiting IDO has been tested as a promising strategy to tackle the immunosuppressive microenvironment of tumors.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IDO
IDO2 (IDO2),IDO2,IDO2,169355,Tryptophan metabolism,T-cell targeted immunomodulator,IDO2 is an enzyme with similar sequence and function to IDO but IDO2 has much narrower expression among tissues and much less enzymatic activities.,
IFNAR1 (IFNAR1),IFNAR1,IFNAR1,3454,JAK/STAT Signaling Pathway,Other immunomodulator,IFNAR1 is one of the two subunits of the receptor for type I interferons. The activation of the receptor leads to the activation of downstream signaling molecules through STAT1/2 pathway.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IFNAR1
IFNB1 (IFNB),IFNB1,IFNB,3456,JAK/STAT Signaling Pathway,Other immunomodulator,"Interferon beta is the cytokine that binds to interferon receptor. It has 2 isoforms, interferon beta 1 and 2.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IFNB
IFNAR2 (IFNAR2),IFNAR2,IFNAR2,3455,JAK/STAT Signaling Pathway,Other immunomodulator,IFNAR2 is one of the two subunits of the receptor for type I interferons. The activation of the receptor leads to the activation of downstream signaling molecules through STAT1/2 pathway.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IFNAR2
IFNGR1 (IFNGR1),IFNGR1,IFNGR1,3459,JAK/STAT Signaling Pathway,Other immunomodulator,IFNGR1 is one of the two subunits of interferon-gamma receptor. The activation of the receptor leads to the activation of downstream JAK/STAT pathway that promotes inflammatory responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IFNGR1
IFNGR2 (IFNGR2),IFNGR2,IFNGR2,3460,JAK/STAT Signaling Pathway,Other immunomodulator,IFNGR2 is one of the two subunits of interferon-gamma receptor. The activation of the receptor leads to the activation of downstream JAK/STAT pathway that promotes inflammatory responses.,
IGF1 (IGF1),IGF1,IGF1,3479,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,IGF1 is a hormone that promotes cell growth. Its levels are elevated in certain tumors and reducing its levels is a target for cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IGF1
IGF1R (IGF1R),IGF1R,IGF1R,3480,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"IGF1R is the receptor for IGF1, and this hormone receptor promote the cancer cell growth and anti-apoptosis function. It is a target for cancer therapy.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IGF1R
IGF2 (IGF2),IGF2,IGF2,3481,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,IGF2 is a hormone that promotes cell growth. It is also highly expressed in certain cancers and reducing its levels is a strategy for cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IGF2
IGFBP2 (IGFBP2),IGFBP2,IGFBP2,3485,Myometrial Relaxation and Contraction Pathways,Targeted by Other Immuno-Oncology Therapy Type,IGFBP2 is highly expressed in ovarian cancer cells and is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IGFBP2
IL10 (IL10),IL10,IL10,3586,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,IL-10 is traditionally believed to be an immunosuppressive cytokine that inhibits JAK/STAT pathway. Recent studies suggest IL-10 can also elevate the anti-tumor immunity through the interferon-gamma and CD8+ T cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL10
IL10RA (IL10RA),IL10RA,IL10RA,3587,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"IL10RA is a receptor for interleukin 10. This protein is structurally related to interferon receptors. It has been shown to mediate the immunosuppressive signal of interleukin 10, and thus inhibits the synthesis of proinflammatory cytokines.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL10RA
IL12A (IL12),IL12A,IL12,3592,Toll-like Receptor Signaling Pathway,T-cell targeted immunomodulator,IL12 is cytokine that help the differentiation of T cells to Th1 cells. It also have other functions to promote the growth of other immune cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL12
IL12RB1 (IL12RB1),IL12RB1,IL12RB1,3594,Toll-like Receptor Signaling Pathway,T-cell targeted immunomodulator,IL12RB1 encodes the beta 1 subunit of IL12R. The two units together form the functional receptor and its activation leads to the downstream signal activation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL12RB1
IL13 (IL13),IL13,IL13,3596,Cytokine-cytokine receptor interaction,Other immunomodulator,"IL13 is reported to have similar function to IL-4. It mainly involves in immune response to parasite infection. However, recent studies show that extrinsic expression of IL-13 may enhance anti-tumor immunity.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL13
IL13RA1 (IL13RA1),IL13RA1,IL13RA1,3597,JAK/STAT Signaling Pathway,Other immunomodulator,IL13RA1 is the subunit of IL13 receptor.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL13RA1
IL13RA2 (IL13RA2),IL13RA2,IL13RA2,3598,Cytokine-cytokine receptor interaction,Other immunomodulator,"IL13RA2 binds much stronger to IL13 than IL13 receptor itself, and it works as a negative regulator of IL13. It is highly expressed in certain tumors, especially in glioblastoma and therefore an attractive target.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL13RA2
IL15 (IL15),IL15,IL15,3600,Cytokine-cytokine receptor interaction,Other immunomodulator,IL15 is secreted by mononuclear phagocytes and its expression activates innate immunity against viral infection. The cytokine is reported to be involved in T-cell lymphoma and therefore a target for this disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL15
IL17A (IL17A),IL17A,IL17A,3605,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,IL17A is one subtype of IL17 cytokine and it induces a various of inflammatory responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL17A
IL17B (IL17B),IL17B,IL17B,27190,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,IL17B is one subtype of IL17 cytokine and it induces a various of inflammatory responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL17B
IL1B (IL1B),IL1B,IL1B,3553,IL-1 signaling pathway,Other immunomodulator,Interleukin 1 beta is a cytokine that involves in autoimmune disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL1B
IL1R1 (IL1R1),IL1R1,IL1R1,3554,IL-1 signaling pathway,Other immunomodulator,IL1R1 is the receptor for IL1 alpha and IL1 beta.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL1R1
IL1RAP (IL1R3),IL1RAP,IL1R3,3556,IL-1 signaling pathway,T-cell targeted immunomodulator,IL1R3 is an accessory protein to IL1 receptor.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL1R3
IL21R (IL21R),IL21R,IL21R,50615,JAK/STAT Signaling Pathway,T-cell targeted immunomodulator,IL21R is the receptor for cytokine IL21.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL21R
IL23R (IL23R),IL23R,IL23R,149233,JAK/STAT Signaling Pathway,T-cell targeted immunomodulator,"IL23R is the receptor for cytokine IL23. Engagement of IL23 leads to the activation of JAK/STAT pathway, which promotes immune cell activation and proliferation.",
IL2RB (IL2RB),IL2RB,IL2RB,3560,Inflammatory Response Pathway,T-cell targeted immunomodulator,IL2RB is a subunit of IL-2 receptor.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL2RB
IL1F9 (IL36G),IL1F9,IL36G,56300,Cytokine-cytokine receptor interaction,Other immunomodulator,IL36-gamma binds to its receptor and activate immune cell functions.,
IL6 (IL6),IL6,IL6,3569,Toll-like Receptor Signaling Pathway,Other immunomodulator,IL6 is secreted by T cells and macrophages and it induces immune responses. It is the major cytokine that is responsible for the cytokine release syndrome accompanying CAR-T therapies for blood cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL6
IL6R (IL6R),IL6R,IL6R,3570,Toll-like Receptor Signaling Pathway,T-cell targeted immunomodulator,IL6R is the receptor for IL6.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL6R
IL8 (IL8),IL8,IL8,3576,Toll-like Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"IL8 is the ligand for CXCR1 and CXCR2, and it is a chemokine that helps the migration of neutrophils. As neutrophils generally promote tumor growth, inhibition of IL8 may reduce neutrophil migration into tumor and therefore reduce tumor growth.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL8
IL9R (IL9R),IL9R,IL9R,3581,Toll-like Receptor Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,IL9R is the receptor for IL9.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL9R
ITGB7 (Integrin beta-7),ITGB7,Integrin beta-7,3695,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,Integrin beta-7 is highly expressed by multiple myeloma cells and is a target for this disease.,
IRAK1 (IRAK1),IRAK1,IRAK1,3654,Toll-like Receptor Signaling Pathway,Other immunomodulator,"IRAK1 is associated with IL-1 receptor and the binding of IL1 to IL1R leads to the activation of this kinase, which initiates subsequent signaling pathway within the cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IRAK1
IRAK4 (IRAK4),IRAK4,IRAK4,51135,Toll-like Receptor Signaling Pathway,Other immunomodulator,IRAK4 is a protein kinase involves in toll-like receptors and T-cell receptor. IRAK4 involves in inflammatory disease and certain types of lymphoma.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IRAK4
ITGB5 (ITGB5),ITGB5,ITGB5,3693,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,ITGB5 is over expressed in glioblastoma and therefore is a target for delivery of therapies that are designed to treat this disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ITGB5
JAK1 (JAK1),JAK1,JAK1,3716,JAK/STAT Signaling Pathway,T-cell targeted immunomodulator,JAK1 is a member of the JAK family. JAK1 interacts with the common gamma chain of type I cytokine receptors. JAK1 relies the signal from those receptors to the downstream signal molecules.,
JAK2 (JAK2),JAK2,JAK2,3717,JAK/STAT Signaling Pathway,T-cell targeted immunomodulator,"JAK2 is a member of the JAK family. JAK1 relies signal from the type II cytokine receptors, GM-CSF receptor family, and gp130 receptor family and the single-chain receptors. JAK2 relies the signal from those receptors to the downstream signal molecules.",
JAK3 (JAK3),JAK3,JAK3,3718,JAK/STAT Signaling Pathway,T-cell targeted immunomodulator,JAK3 involves in the receptor signaling mediated by the common gamma chain of type I receptors.,
KIF20A (KIF20A),KIF20A,KIF20A,10112,Antigen,Targeted by Other Immuno-Oncology Therapy Type,KIF20A was found to be highly expressed in pancreatic cancer and is a target of cancer vaccine for this cancer type.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;KIF20A
KIR2DL1 (KIR2DL1),KIR2DL1,KIR2DL1,3802,Adaptive Immune System,Other immunomodulator,"KIR2DL1 is expressed by natural killer cells and certain subtypes of T cells, and its engagement leads to inhibitory signal downstream.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;KIR2DL1
KIR3DL2 (KIR2DL2),KIR3DL2,KIR2DL2,3812,Adaptive Immune System,Other immunomodulator,"KIR2DL2 is expressed by natural killer cells and certain subtypes of T cell, and its engagement leads to inhibitory signal downstream.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;KIR2DL2
KIR3DL3 (KIR2DL3),KIR3DL3,KIR2DL3,115653,Adaptive Immune System,Other immunomodulator,"KIR2DL3 is expressed by natural killer cells and certain subtypes of T cell, and its engagement leads to inhibitory signal downstream.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;KIR2DL3
KRAS (KRAS),KRAS,KRAS,3845,MAPK Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"KRAS is a member of the RAS family, and it plays essential role in many types of cancer. KRAS mutation is reported to be the driver gene mutation in a large number of cancer cases. Therapies against particular mutations of KRAS are being developed.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;KRAS
LAG3 (LAG-3),LAG3,LAG-3,3902,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"LAG-3 binds to MHCII, which is main binding partner of CD4. By hijacking MHCII from CD4, LAG-3 negatively regulate the activation of CD4+ T cell's TCR signaling pathway. LAG-3 is reported to help maintain CD8 T cell function too. LAG-3 is an immune checkpoint molecule.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;LAG-3
NR1H3 (LXRA),NR1H3,LXRA,10062,Nuclear Receptors,Other immunomodulator,"LXRA and LXRB, two isoforms of LXR, are key regulator of macrophage function. Activation of LXR educate macrophages to adopt an anti-inflammatory phenotype.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LXRA
NR1H2 (LXRB),NR1H2,LXRB,7376,Nuclear Receptors,Other immunomodulator,"LXRA and LXRB, two isoforms of LXR, are key regulator of macrophage function. Activation of LXR educate macrophages to adopt an anti-inflammatory phenotype.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LXRB
MAGEA1 (MAGE-A1),MAGEA1,MAGE-A1,4100,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MAGE-A1 is a member of the MAGE family and it is highly expressed in melanoma and a few other cancer types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MAGE-A1
MAGEA10 (MAGE-A10),MAGEA10,MAGE-A10,4109,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MAGE-A10 is a member of the MAGE family and it is highly expressed in melanoma and a few other cancer types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MAGE-A10
MAGEA3 (MAGE-A3),MAGEA3,MAGE-A3,4102,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MAGE-A3 is a member of the MAGE family and it is highly expressed in melanoma and a few other cancer types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MAGE-A3
MAGEA4 (MAGE-A4),MAGEA4,MAGE-A4,4103,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MAGE-A4 is a member of the MAGE family and it is highly expressed in melanoma and a few other cancer types.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MAGE-A4
MAGEC2 (MAGE-C2),MAGEC2,MAGE-C2,51438,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"MAGE-C2 is a member of the MAGEC gene family. It is not expressed in normal tissues, except for testis, and is expressed in tumors of various histological types.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MAGE-C2
SCGB2A2 (Mammaglobin A),SCGB2A2,Mammaglobin A,4250,Antigen,Targeted by Other Immuno-Oncology Therapy Type,Mammaglobin A is highly expressed by certain types of breast cancer and is a target for vaccine against this disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Mammaglobin A
MAS1 (Mas receptor),MAS1,Mas receptor,4142,GPCRs,Targeted by Other Immuno-Oncology Therapy Type,Mas receptor (MAS1) is a G-protein coupled receptor. Its ligands include adenine and 8-aminoadenine. It is a target of cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;Mas receptor
IFIH1 (MDA5),IFIH1,MDA5,64135,RIG-I-like Receptor Signaling,Other immunomodulator,MDA5 recognizes dsDNA and activate innate immune response. Activation of it is believed to enhance the anti-tumor immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MDA5
MDM2 (MDM2),MDM2,MDM2,4193,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,"MDM2 is a negative regulator of P53 and it is highly expressed in many tumor types, which is a target for cancer vaccine.",
MERTK (MERTK),MERTK,MERTK,10461,Antigen,Other immunomodulator,MERTK is highly expressed in certain cancer cells and is a target for monoclonal antibody therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MERTK
MSLN (Mesothelin),MSLN,Mesothelin,10232,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"Mesothelin is highly expressed in mesothelial cells, and those cells line the pleura, peritoneum, and pericardium. Mesothelin is a target for mesothelioma and other cancer highly expressing this molecule.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Mesothelin
MICB (MICB),MICB,MICB,4277,Adaptive Immune System,Other immunomodulator,MICB is related to MHC I and shares similar structure with MHC I. MICA is a stress-induced ligand for NKG2D and is broadly recognized by NK cells.,
MIF (MIF),MIF,MIF,4282,Cytokine-cytokine receptor interaction,Other immunomodulator,MIF is an inflammatory cytokine and it binds to CD74 and induces acute inflammatory responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MIF
MLANA (MLANA),MLANA,MLANA,2315,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MLANA is found on the surface of melanocytes. It is highly expressed by melanoma cells and therefore a target for this disease.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MLANA
MMP11 (MMP-11),MMP11,MMP-11,4320,Matrix Metalloproteinases,Targeted by Other Immuno-Oncology Therapy Type,"MMP-11 is a member of metalloproteinase family. MMP-11 degrades extracellular matrix. Due to its high expression in tumors, it is a target for cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MMP-11
ABCC1 (MRP1),ABCC1,MRP1,4363,ABC-family proteins mediated transport,Targeted by Other Immuno-Oncology Therapy Type,MRP1 is a membrane transporter and it allows tumor cells to transport many chemotherapeutic compounds out of cancer cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MRP1
MUC1 (MUC1),MUC1,MUC1,4582,Interleukin-4 and Interleukin-13 signaling,Targeted by Other Immuno-Oncology Therapy Type,MUC1 is a glycoprotein and it lines the apical surface of epithelial cells in many tissue. MUC1 is found to highly expressed in highly expressed in many solid tumors and is a target for cancer vaccines and cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MUC1
MUC16 (MUC16),MUC16,MUC16,94025,Antigen,Targeted by Other Immuno-Oncology Therapy Type,MUC16 is biomarker for ovarian cancer due to its high expression. MUC16 is also a target for ovarian cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;MUC16
MYB (MYB),MYB,MYB,4602,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,MYB is a transcription factor. It is highly expressed in colorectal cancer and adenoid cystic carcinoma. It is a target of cancer vaccine against these cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MYB
MYBL2 (MYBL2),MYBL2,MYBL2,4605,EGF-EGFR Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,MYBL2 is a transcription factor and is highly expressed in certain tumor cells. Oncolytic virus has been designed to use MYBL2 as the transcription factor to promote the gene expression of oncolytic genes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MYBL2
MYCN (N-Myc),MYCN,N-Myc,4613,Transcriptional misregulation in cancer,Targeted by Other Immuno-Oncology Therapy Type,N-Myc is a transcription factor and amplification of N-Myc leads to tumorigenesis. Peptides derived from N-Myc are being used as cancer vaccines.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;N-Myc
KLRC1 (NKG2A),KLRC1,NKG2A,3821,Adaptive Immune System,Other immunomodulator,NKG2A dimerizes with CD94 to form an inhibitory receptor on NK cell surface.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;NKG2A
KLRK1 (NKG2D),KLRK1,NKG2D,22914,Adaptive Immune System,Other immunomodulator,NKG2D forms a homodimer and serves as an activating receptor for NK cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;NKG2D
NCR1 (NKp46),NCR1,NKp46,9437,Adaptive Immune System,Other immunomodulator,NKp46 is a cell surface marker for NK cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;NKp46
NLRP3 (NLRP3),NLRP3,NLRP3,114548,NOD receptor signaling pathway,Other immunomodulator,NLRP3 is predominantly expressed by macrophages and it is a component of inflammasome. Activation of inflammasome through NLRP3 is believed to promote the anti-tumor immunity of macrophages.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;NLRP3
NR2F6 (NR2F6),NR2F6,NR2F6,2063,IL-6 signaling pathway,Other immunomodulator,"NR2F5 is found to over expressed in leukemia, ovarian cancer, and endometrial cancer. Strategy to silence its expression in stem cell is being pursued as cancer treatment.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;NR2F6
CTAG1B (NY-ESO-1),CTAG1B,NY-ESO-1,1485,Antigen,Targeted by Other Immuno-Oncology Therapy Type,NY-ESO-1 is found to highly expressed in melanoma with poor prognosis. It is also found to be highly expressed in many other solid tumors. It is a target for cancer vaccine and cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;NY-ESO-1
TNFRSF4 (OX40),TNFRSF4,OX40,7293,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,OX40 is the receptor on T cells and it binds to OX40 ligand. Activation of this receptor improves the survival of activated T cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;OX40
P2RX7 (P2RX7),P2RX7,P2RX7,5027,NOD-like receptor signaling pathway,Other immunomodulator,P2RX7 is found on microglia and macrophages. It plays a role in inflammatory response. Activation of this receptor may increase the anti-tumor immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;P2RX7
TP53 (p53),TP53,p53,7157,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,P53 is a tumor suppressor and plays a pivotal role in controlling tumorigenesis. Cancer therapies are being developed to increase or restore the modified function of P53.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;p53
PASD1 (PASD1),PASD1,PASD1,139135,Antigen,Targeted by Other Immuno-Oncology Therapy Type,PASD1 is highly expressed in various cancer types and is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;PASD1
PTTG1IP (PBF),PTTG1IP,PBF,754,Antigen,Targeted by Other Immuno-Oncology Therapy Type,PBF is found to highly express in pituitary tumors and breast cancer. It is therefore used as a target for cancer vaccines in those tumors.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PBF
PDCD1 (PD-1),PDCD1,PD-1,5133,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,PD-1 is a immune checkpoint molecule and inhibition of it leads to the anti-tumor immunity of T cells. It is the most important target in cancer immunotherapy as of today and many therapies against it have been approved for cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PD-1
CD274 (PD-L1),CD274,PD-L1,29126,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,"PD-L1 is the major ligand to PD-1 and it is highly expressed by cancer cells and other immune cells, especially macrophages and dendritic cells. Inhibiting PD-L1 is a viable method to unleash the anti-tumor immunity of T cells and a few drugs against this target have been approved.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PD-L1
PDCD1LG2 (PD-L2),PDCD1LG2,PD-L2,80380,T-Cell antigen Receptor (TCR) Signaling Pathway,T-cell targeted immunomodulator,PD-L2 is a ligand to PD-1. Its expression is not as wide as PD-L1 and its function in binding PD-1 is not very clear at the moment.,
SILV (PMEL),SILV,PMEL,6490,Antigen,Targeted by Other Immuno-Oncology Therapy Type,PMEL is expressed in melanoma cells. It is a target for cancer vaccine against melanoma.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PMEL
POTED (POTE),POTED,POTE,317754,Antigen,Targeted by Other Immuno-Oncology Therapy Type,POTE is highly expressed in testis and it is target for cancer of testis origin. It is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;POTE
PRAME (PRAME),PRAME,PRAME,23532,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"PRAME is predominantly expressed in human melanoma cells but not in normal tissues, except for testis. It is a target for cancer vaccine and cell therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PRAME
KLK3 (PSA),KLK3,PSA,354,Androgen receptor signaling pathway,Targeted by Other Immuno-Oncology Therapy Type,"PSA is secreted by the epithelial cells of prostate gland. PSA level is elevated in prostate cancer patients, and it is a diagnosis marker for this disease. PSA is also a target for cancer vaccines against prostate cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PSA
PSCA (PSCA),PSCA,PSCA,8000,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"PSCA is a membrane protein that is highly expressed in prostate, kidney, colon, bladder, placenta, and stomach. It is a target of cell therapies for cancer of those tissue origins.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PSCA
PVRIG (PVRIG),PVRIG,PVRIG,79037,TIGIT pathway,T-cell targeted immunomodulator,"PVRIG is believed to be a immune checkpoint molecule, and PVRL2 is its ligand. Disruption of this association leads to enhanced T cell immunity against cancer cells and this inhibition increases T cell proliferation.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;PVRIG
RHOC (RhoC),RHOC,RhoC,389,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,RhoC is GTPase and it is frequently mutated in cancers. Mutated RhoC is a target for cancer vaccines.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;RhoC
DDX58 (RIG-I),DDX58,RIG-I,23586,RIG-I-like Receptor Signaling,Other immunomodulator,RIG-I is a pattern recognition receptor for viruses. Activation of it leads to inflammatory response and is a target for cancer immunotherapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;RIG-I
ROR1 (ROR1),ROR1,ROR1,4919,Wnt Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,ROR1 is found to highly express in cancer stem cell and play a role in tumor migration and metastasis. It is a cell membrane receptor and therefore a target for cancer cell therapy.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;ROR1
ROR2 (ROR2),ROR2,ROR2,4920,Wnt Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,ROR2 is cell membrane receptor and promotes cell growth of certain cancer cells. It is a target for cancer cell therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ROR2
RORC (RORC),RORC,RORC,6097,Nuclear Receptors,Other immunomodulator,RORC is the gene that encodes ROR-gamma. ROR-gamma is an important nuclear receptor that plays important role in assisting CD4+ T cells to differentiating to Th17 cells. Th17 cells generate inflammatory cytokine and enhance anti-tumor immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;RORC
SIM2 (SIM-2),SIM2,SIM-2,6493,Antigen,Targeted by Other Immuno-Oncology Therapy Type,"The short form of SIM2, called SIM2s, has tumor suppressive properties. It is a target of cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;SIM-2
SIRPA (SIRPA),SIRPA,SIRPA,140885,JAK/STAT Signaling Pathway,Other immunomodulator,"SIRPA is an inhibitory ligand that binds to CD47, the ""do not eat me"" receptor from phagocytes. Binding of SIRPA to CD47 prevents phagocytosis. Blocking of this ligand leads to increased phagocytosis of tumor cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;SIRPA
SOX2 (SOX2),SOX2,SOX2,6657,Cell Differentiation,Targeted by Other Immuno-Oncology Therapy Type,SOX is an transcription factor and it plays role in certain tumor types. It is a target for cancer vaccine.,
SPAM1 (SPAM1),SPAM1,SPAM1,6677,Hyaluronidase,Targeted by Other Immuno-Oncology Therapy Type,"SPAM1 degrades hyaluronic acid, a major structural proteoglycan found in extracellular matrices and basement membranes. SAPM1 as a hyaluronidase degrades extracellular matrix, which block the therapeutic effects of many cancer drugs. Strategies to increase hyaluronidase level are used to increase cancer drugs effectiveness.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;SPAM1
SSTR2 (SSTR2),SSTR2,SSTR2,6752,GPCRs,Targeted by Other Immuno-Oncology Therapy Type,SSTR acts on many sites to inhibit the release of hormones and other secretory proteins. SSTR2 is also highly expressed in several cancer types and a target for cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;SSTR2
SSX2 (SSX2),SSX2,SSX2,6757,Transcriptional misregulation in cancer,Targeted by Other Immuno-Oncology Therapy Type,SSX2 is highly expressed by synovial sarcoma cells. It is a target for cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;SSX2
STAT1 (STAT1),STAT1,STAT1,6772,JAK/STAT Signaling Pathway,Other immunomodulator,"STAT1 is member of STAT family and it generally responds to IFN-alpha, IFN-beta, IFN-gamma, EGF, PDGF, and IL-6. Small molecules to activate STAT1 are drug candidates to boost immune response against cancer.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;STAT1
STAT3 (STAT3),STAT3,STAT3,6774,JAK/STAT Signaling Pathway,Other immunomodulator,"STAT3 is member of STAT family and it generally responds to IFN-alpha, IFN-beta, IFN-gamma, EGF, PDGF, and IL-6. STAT3 is essential for the differentiation of Th17 cells, which generate inflammatory cytokines to promote anti-tumor immunity.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;STAT3
TMEM173 (STING),TMEM173,STING,340061,RIG-I-like Receptor Signaling,Other immunomodulator,"STING plays an important role in innate immunity. STING induces type I interferon production, which leads to activated innate immune response. Agonists against STING are being developed as cancer immunotherapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;STING
BIRC5 (Survivin),BIRC5,Survivin,332,Apoptosis,Targeted by Other Immuno-Oncology Therapy Type,"Survivin is a member of inhibitors of apoptosis (IAP) family and it allows cells to resist apoptosis. It is highly expressed in a few cancers, especially in breast cancer and lung cancer. It is a target for many cancer vaccines and a few cell therapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Survivin
TACSTD2 (TASTD2),TACSTD2,TASTD2,4070,Antigen,Targeted by Other Immuno-Oncology Therapy Type,TASTD2 is a carcinoma-associated protein expressed on cancer cells. It is a target for CD3-targeted bispecific antibodies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TASTD2
TDO2 (TDO),TDO2,TDO,6999,Tryptophan metabolism,T-cell targeted immunomodulator,TDO is an enzyme that metabolizes tryptophan into kynurenine. Kynurenine is a signaling molecule that binds to immune cells and induce immunosuppressive function. Inhibition of TDO leads to enhanced anti-tumor immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TDO
TERT (TERT),TERT,TERT,7015,Telomere pathway,Targeted by Other Immuno-Oncology Therapy Type,TERT prolongs the telomere of cancer cells and enhance their survival.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TERT
TFDP3 (TFDP3),TFDP3,TFDP3,51270,Antigen,Targeted by Other Immuno-Oncology Therapy Type,This gene encodes a member of the DP family of transcription factors. These factors heterodimerize with E2F proteins to enhance their DNA-binding activity and promote transcription from E2F target genes. This protein functions as a negative regulator and inhibits the DNA binding and transcriptional activities of E2F factors. It is a target of cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TFDP3
TGFB1 (TGFB1),TGFB1,TGFB1,7040,TGF-beta Signaling Pathway,Other immunomodulator,"TGF-beta1 is one of the 4 isoforms of TGF-beta, and this molecule predominantly presents immunosuppressive functions on immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TGFB1
TGFB2 (TGFB2),TGFB2,TGFB2,7042,TGF-beta Signaling Pathway,Other immunomodulator,"TGF-beta2 is one of the 4 isoforms of TGF-beta, and this molecule predominantly presents immunosuppressive functions on immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TGFB2
TGFBR1 (TGFBR1),TGFBR1,TGFBR1,7046,TGF-beta Signaling Pathway,Other immunomodulator,"TGFBR1 forms the heterodimer complex of TGF receptor, which binds to TGF and leads to the activation of the pathway. Activation of TGF-beta receptor plays dominantly immunosuppressive role in the immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TGFBR1
TGFBR2 (TGFBR2),TGFBR2,TGFBR2,7048,TGF-beta Signaling Pathway,Other immunomodulator,"TGFBR2 is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. Activation of TGF-beta receptor plays dominantly immunosuppressive role in the immune cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TGFBR2
TIGIT (TIGIT),TIGIT,TIGIT,201633,TIGIT pathway,T-cell targeted immunomodulator,TIGIT is immune checkpoint molecule and cell surface receptor. It is highly expressed on activated T cells. TIGIT binds to its ligands CD155 and CD112. Blocking the binding of ligands to TIGIT is promising strategies to enhance T cell's anti-tumor immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TIGIT
HAVCR2 (TIM-3),HAVCR2,TIM-3,84868,Gelactin-9/TIM-3 pathway,T-cell targeted immunomodulator,TIM-3 is immune checkpoint and cell surface receptor. Its ligand is mainly Galectin 9. TIM-3 is highly expressed in tumor-infiltrating leukocytes. Blocking its binding with its ligand is pursued by many cancer immunotherapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TIM-3
TIMP3 (TIMP3),TIMP3,TIMP3,7078,Matrix Metalloproteinases,Targeted by Other Immuno-Oncology Therapy Type,TIMP3 is an inhibitor of matrix metalloproteinases. TIMP3 is incorporated into oncolytic virus as a product to prevent the degradation of extracellular matrix.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TIMP3
TLR2 (TLR2),TLR2,TLR2,7097,Toll-like Receptor Signaling Pathway,Other immunomodulator,"TLR2 is a membrane protein and it binds with lipid-containing pathogen-associated molecular patterns (PAMPs), such as lipoteichoic acid and di- and tri-acylated cysteine-containing lipopeptides.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR2
TLR3 (TLR3),TLR3,TLR3,7098,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR3 is a member of TLR family and it recognizes dsRNA. Its activation leads to innate immunity activation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR3
TLR4 (TLR4),TLR4,TLR4,7099,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR4 is a surface receptor and binds to lipopolysaccharide (LPS). It is a member of TLR family and it activates innate immune responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR4
TLR5 (TLR5),TLR5,TLR5,7100,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR5 is a surface receptor and binds to bacterial flagellum. It is a member of TLR family and it activates innate immune responses.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR5
TLR7 (TLR7),TLR7,TLR7,51284,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR7 recognizes single-strand RNA in endosomes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR7
TLR8 (TLR8),TLR8,TLR8,51311,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR8 recognizes GU-rich single-stranded RNA and G-rich oligonucleotides. It is endosomal receptor recognizing ssRNA too.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR8
TLR9 (TLR9),TLR9,TLR9,54106,Toll-like Receptor Signaling Pathway,Other immunomodulator,TLR9 recognizes CpG sequences in DNA molecules. TLR9 generally locates in endoplasmic reticulum.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TLR9
TNF (TNF),TNF,TNF,7124,TNF alpha Signaling Pathway,Other immunomodulator,TNF is cytokine and is involved in acute inflammation. It has wide range of functions on immune cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TNF
TOP1 (TOP1),TOP1,TOP1,7150,Transcriptional misregulation in cancer,Targeted by Other Immuno-Oncology Therapy Type,"TOP1 is a DNA topoisomerase, an enzyme controlling the topologic states of DNA during transcription. Targeting this molecule is a strategy for stem cell therapy for cancer.",
TNFSF10 (TRAIL),TNFSF10,TRAIL,8743,Apoptosis,Targeted by Other Immuno-Oncology Therapy Type,"TRAIL is a ligand for death receptor 4 (DR4) and 5 (DR5). It also binds to DcR2, whose activation is believed to promote inflammation. Therefore, agonists similar to TRAIL are being evaluated as cancer immunotherapies.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TRAIL
DCT (TRP2),DCT,TRP2,1638,Neural Crest Differentiation,Targeted by Other Immuno-Oncology Therapy Type,"TRP2 is over expressed by a variety of cancers, and it is a target for cancer vaccine.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;TRP2
TSHR (TSHR),TSHR,TSHR,7253,Thyroxine (Thyroid Hormone) Production,Targeted by Other Immuno-Oncology Therapy Type,TSHR is a G protein-coupled receptor. It is the receptor of thyroid-stimulating hormone (TSH). It is found on the surface of thyroid epithelial cells. It is highly expressed on thyroid cancer and target for cancer therapies.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TSHR
TNFSF12 (TWEAK),TNFSF12,TWEAK,8742,Cytokine-cytokine receptor interaction,Other immunomodulator,TWEAK is the ligand for TWEAK receptor (TWEAKR). This pair is believed to have pro-inflammatory function.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TWEAK
TYK2 (TYK2),TYK2,TYK2,7297,JAK/STAT Signaling Pathway,Other immunomodulator,"TYK2 is the first member of JAK family, along with JAK1, JAK2, and JAK3. Tyk2 can be activated by IL12 and type I interferon, as well as IL10.",
TYRO3 (TYRO3),TYRO3,TYRO3,7301,Antigen,Other immunomodulator,TYRO3 is highly expressed in certain cancers and therefore a target for cancer therapy.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TYRO3
TYR (Tyrosinase),TYR,Tyrosinase,7299,Dopamine metabolism,Targeted by Other Immuno-Oncology Therapy Type,Tyrosinase is believed to be highly expressed by myeloid derived suppressor cells (MDSCs). It is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;Tyrosinase
LY6K (URLC10),LY6K,URLC10,54742,Antigen,Targeted by Other Immuno-Oncology Therapy Type,URLC10 is a tumor-associated antigen highly expressed in NSCLC. It is also a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;URLC10
VEGFA (VEGFA),VEGFA,VEGFA,7422,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,VEGFA exerts it primary functions through the interaction with VEGFR1 and 2. The activation of VEGFR1/2 by VEGFA also leads to macrophage migration.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;VEGFA
FLT1 (VEGFR1),FLT1,VEGFR1,2321,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"VEGFR1 binds to VEGFA and VEGFB, but its function is not well understood.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;VEGFR1
KDR (VEGFR2),KDR,VEGFR2,3791,VEGFA-VEGFR2 Signaling Pathway,Targeted by Other Immuno-Oncology Therapy Type,"VEGFR2 binds to VEGFA, VEGFC , and VEGFE. It is the main subtype of VEGFR molecule to relay the VEGFR signaling pathway.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;VEGFR2
C10orf54 (VISTA),C10orf54,VISTA,64115,Innate Immune System,T-cell targeted immunomodulator,"VISTA is an immune checkpoint molecule. It is highly expressed in tumor infiltrating leukocytes. VISTA can be both a ligand and a receptor, and both functions lead to immunosuppressive phenotype on T cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;VISTA
VSIG4 (VSIG-4),VSIG4,VSIG-4,11326,Complement system,T-cell targeted immunomodulator,"VSIG-4 is expressed on macrophages, and it may interact with T cells and inhibit normal T cell anti-tumor functions.",
WT1 (WT1),WT1,WT1,7490,Transcriptional misregulation in cancer,Targeted by Other Immuno-Oncology Therapy Type,WT1 is the target for cancer vaccines and cell therapies as it is highly expressed in many types of cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;WT1
ZP3 (ZP3),ZP3,ZP3,7784,Antigen,Targeted by Other Immuno-Oncology Therapy Type,ZP3 is highly expressed in some cancers but not in normal mature cells. It is a target for cancer vaccine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ZP3
ADORA3 (ADORA3),ADORA3,ADORA3,140,Adaptive Immune System,T-cell targeted immunomodulator,ADORA3 is a GPCR involved in a variety of intracellular signaling.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ADORA3
ATM (ATM),ATM,ATM,472,DNA Damage Response,Other immunomodulator,ATM is a serine/threonine kinase involved in DNA double-strand break damage response.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ATM
ATR (ATR),ATR,ATR,545,DNA Damage Response,Other immunomodulator,ATR is a serine/threonine kinase involved in response to single strand DNA breaks.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ATR
FMNL1 (FMNL1),FMNL1,FMNL1,752,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,"FMNL1 is implicated in morphogenesis, cytokinesis, and cell polarity.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;FMNL1
CALR (CALR),CALR,CALR,811,Misfolded Protein,Targeted by Other Immuno-Oncology Therapy Type,Calreticulin binds misfolded protein and prevents export from the ER to the Golgi apparatus.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CALR
CASP9 (CASP9),CASP9,CASP9,842,Apoptosis,Targeted by Other Immuno-Oncology Therapy Type,Caspase-9 is an initiator caspase in apoptotic pathway.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CASP9
CD1A (CD1A),CD1A,CD1A,909,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,CD1 proteins mediate the presentation of primarily lipid and glycolipid antigens of self or microbial origin to T cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD1A
CD5 (CD5),CD5,CD5,921,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,CD5 is expressed on T cell surface.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD5
CD8A (CD8),CD8A,CD8,925,Cytokine Signaling in Immune system,T-cell targeted immunomodulator,CD8 is a coreceptor of T cell receptor.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD8
CD9 (MIC3),CD9,MIC3,928,Innate Immune System,Other immunomodulator,"MIC3 or CD9 is a cell surface glycoprotein, known to complex with integrins and other transmembrane 4 superfamily proteins.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MIC3
CD37 (CD37),CD37,CD37,951,Cellular responses to external stimuli,Other immunomodulator,"CD37 is expressed in highest abundance on mature B cells, and to a lesser extent on T cells and myeloid cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD37
CDH17 (CDH17),CDH17,CDH17,1015,Adherens junctions interactions,Targeted by Other Immuno-Oncology Therapy Type,Cadherin17 is an adhesion molecule.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CDH17
CDK7 (CAK1),CDK7,CAK1,1022,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,CAK1 or CDK7 mediates progression through the cell cycle.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CAK1
CGB (CGB3),CGB,CGB3,1082,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,Chorionic gonadotropin subunit beta 3 is a glycoprotein.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CGB3
CCR5 (CCR5),CCR5,CCR5,1234,Chemokine signaling,Targeted by Other Immuno-Oncology Therapy Type,C-C motif chemokine receptor 5 is cell surface protein on white blood cells that acts as a receptor for chemokines.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCR5
CLDN3 (CLDN3),CLDN3,CLDN3,1365,Cell junction organization,Targeted by Other Immuno-Oncology Therapy Type,Claudin 3 is involved in tight junctions.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CLDN3
MAPK14 (MAPK14),MAPK14,MAPK14,1432,Cytokine Signaling in Immune system,Other immunomodulator,Mitogen-activated protein kinase 14 or p38 alpha is implicated in diverse cellular functions.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MAPK14
CYP1B1 (CYP1B1),CYP1B1,CYP1B1,1545,Fatty acid metabolism,Targeted by Other Immuno-Oncology Therapy Type,Cytochrome P450 family 1 subfamily B member 1 acts in drug metabolism and lipid synthesis.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CYP1B1
CD55 (CD55),CD55,CD55,1604,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,CD55 is a glycoprotein.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD55
EMR1 (EMR1),EMR1,EMR1,2015,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,EMR1 is an adhesion GPCR.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;EMR1
EPHA3 (EPHA3),EPHA3,EPHA3,2042,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,EPH receptor A3 is protein-tyrosine kinase implicated in development.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;EPHA3
FCER2 (CD23),FCER2,CD23,2208,IL4 Signaling,Targeted by Other Immuno-Oncology Therapy Type,"CD23 is an antibody isotype involved in allergy and resistance to parasites, and important in regulating IgE levels.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD23
FCGR1A (CD64),FCGR1A,CD64,2209,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,CD64 is a glycoprotein found on macrophages and monocytes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD64
FGF5 (FGF5),FGF5,FGF5,2250,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,"Fibroblast growth factor 5 involved in different signaling cascades including PI3K, RAS-MAPK, and STAT.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;FGF5
LRRC32 (GARP),LRRC32,GARP,2615,TGFb Signaling,T-cell targeted immunomodulator,"GARP is a regulator of TGFB1, TGFB2, and TGFB3.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GARP
GDNF (GDNF),GDNF,GDNF,2668,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,GDNF or glial cell derived neurotrophic factor is secreted ligand of the TGF-beta superfamily of proteins.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GDNF
GHRH (GHRH),GHRH,GHRH,2691,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,Growth hormone releasing hormone triggers the release of growth hormone.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GHRH
GNRH1 (LHRH),GNRH1,LHRH,2796,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,Gonadotropin releasing hormone 1 leads to the synthesis and secretion of gonadotropins LH and FSH.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LHRH
CCR10 (CCR10),CCR10,CCR10,2826,Cytokine Signaling in Immune system,Other immunomodulator,CCR10 is a chemokine receptor and is involved in T cell-mediated skin inflammation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCR10
CXCR3 (CXCR3),CXCR3,CXCR3,2833,Chemokine signaling,Other immunomodulator,CXCR3 or C-X-C motif chemokine receptor 3 is expressed on activated T lymphocytes and NK cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CXCR3
GUCY2C (GUCY2C),GUCY2C,GUCY2C,2984,GC-C Signaling,Targeted by Other Immuno-Oncology Therapy Type,Guanylate cyclase 2C is a key receptor for heat-stable enterotoxins.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GUCY2C
HDAC2 (HDAC2),HDAC2,HDAC2,3066,Chromatin modifying enzymes,Other immunomodulator,Histone deacetylase 2 removes acetyl groups from the lysine residues at the N-terminal of core histones.,
HMMR (CD168),HMMR,CD168,3161,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,CD168 or Hyaluronan mediated motility receptor is overexpressed in breast cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD168
IL1A (IL1A),IL1A,IL1A,3552,Cytokine Signaling in Immune system,Other immunomodulator,Interleukin 1 alpha is produced by activated macrophages and can lead to the activation of tumor necrosis factor-alpha.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL1A
IL4 (IL4),IL4,IL4,3565,Cytokine Signaling in Immune system,T-cell targeted immunomodulator,interleukin 4 induces naïve helper T cells to differentiate.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL4
IL4R (IL4R),IL4R,IL4R,3566,Cytokine Signaling in Immune system,T-cell targeted immunomodulator,interleukin 4 receptor binds its ligand to induce naïve helper T cells to differentiate.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL4R
IL6ST (CD130),IL6ST,CD130,3572,Cytokine Signaling in Immune system,Other immunomodulator,CD130 or interleukin 6 signal transducer is a subunit of IL6-receptor family.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD130
IL18 (IL18),IL18,IL18,3606,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,Interleukin 18 induces interferon-gamma production and may modulate both innate and adaptive immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;IL18
ITGA4 (ITGA4),ITGA4,ITGA4,3676,Adaptive Immune System,Other immunomodulator,integrin subunit alpha 4 is involved in lymphocyte migration.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ITGA4
LGALS3BP (LGALS3BP),LGALS3BP,LGALS3BP,3959,Cell-cell signaling,Other immunomodulator,Galectin 3 binding protein is elevated in the serum of some cancer patients and may be implicated in immune response associated with natural killer cells and lymphokine-activated killer cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LGALS3BP
LTA (LTA),LTA,LTA,4049,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,Lymphotoxin alpha is a member of the tumor necrosis factor family and is a cytokine produced by lymphocytes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LTA
MCL1 (MCL1),MCL1,MCL1,4170,Apoptosis,Targeted by Other Immuno-Oncology Therapy Type,"MCL1 is BCL2 family apoptosis regulator, whose alternative splicing can either inhibit or promote apoptosis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MCL1
CD99 (MIC2),CD99,MIC2,4267,Adaptive Immune System,Other immunomodulator,MIC2 or CD99 is expressed on all leukocytes and may augment T-cell adhesion.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MIC2
CXCL9 (CXCL9),CXCL9,CXCL9,4283,Chemokine signaling,T-cell targeted immunomodulator,C-X-C motif chemokine ligand 9 is involved in immune cell differentiation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CXCL9
MMP2 (MMP2),MMP2,MMP2,4313,Matrix Metalloproteinase,Targeted by Other Immuno-Oncology Therapy Type,MMP2 is a matrix metalloproteinase involved in the breakdown of extracellular matrix.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MMP2
MUC2 (MUC2),MUC2,MUC2,4583,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,Mucin 2 coats the epithelia of mucus-membrane containing organs.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MUC2
NFKB1 (NFKB),NFKB1,NFKB,4790,Cytokine Signaling in Immune system,Other immunomodulator,Nuclear factor kappa B subunit 1 is a part of a protein complex that controls DNA transcription and regulates immune response to infection.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;NFKB
YBX1 (YBX1),YBX1,YBX1,4904,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,"Y-box binding protein 1 is target in cancer therapy, since it supports the replication of adenovirus oncolytic viruses.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;YBX1
KLK7 (KLK7),KLK7,KLK7,5650,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,"Kallikrein related peptidase 7 is a serine protease, whose overexpression may be a route for metastasis in solid tumors.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;KLK7
PTGER2 (PTGER2),PTGER2,PTGER2,5732,Signal Transduction,Other immunomodulator,"Prostaglandin E receptor 2 is a GPCR, which can regulate G protein cell signaling pathways. Functions in neutrophils modulate TNFa and IL6 production.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;PTGER2
PTGER4 (PTGER4),PTGER4,PTGER4,5734,Signal Transduction,Other immunomodulator,Prostaglandin E receptor 4 is one of the receptors for prostaglandin E2 and can activate T-cell factor signaling.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;PTGER4
PTPN11 (NS1),PTPN11,NS1,5781,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,"NS1 or protein tyrosine phosphatase, non-receptor type 11 is a signaling molecule that regulates many cellular processes.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;NS1
RB1 (RB),RB1,RB,5925,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,RB or RB transcriptional corepressor 1 is a negative regulator of the cell cycle and was the first tumor suppressor gene found.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;RB
ROBO1 (ROBO1),ROBO1,ROBO1,6091,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,ROBO1 or roundabout guidance receptor 1 is a member of the immunoglobulin gene superfamily.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ROBO1
CCL2 (CCL2),CCL2,CCL2,6347,Chemokine signaling,Targeted by Other Immuno-Oncology Therapy Type,CCL2 or C-C motif chemokine ligand 2 binds chemokine receptors CCR2 and CCR4 with chemotactic activity on monocytes and basophils.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CCL2
SELPLG (CD162),SELPLG,CD162,6404,Cell surface interactions,Other immunomodulator,"CD162 or selectin P ligand is a glycoprotein that functions as a high affinity counter-receptor for the cell adhesion molecules P-, E- and L- selectin expressed on myeloid cells and stimulated T lymphocytes.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;CD162
TGFB3 (TGFB3),TGFB3,TGFB3,7043,Signal Transduction,Other immunomodulator,Transforming growth factor beta 3 is a secreted ligand in the TGF-beta superfamily of proteins.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TGFB3
TK1 (TK1),TK1,TK1,7083,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,TK1 or thymidine kinase 1 catalyzes the addition of a gamma-phosphate group to thymidine.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TK1
TLR1 (CD281),TLR1,CD281,7096,Adaptive Immune System,Other immunomodulator,CD281 or Toll-like receptor 1 is a member of Toll-like receptor family and plays a role in pathogen recognition and activation of innate immunity.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CD281
TNFRSF1A (TNFRSF1A),TNFRSF1A,TNFRSF1A,7132,Cytokine Signaling in Immune system,Other immunomodulator,"TNFRSF1A is a TNF receptor superfamily member. It plays a role in cell survival, apoptosis, and survival.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF1A
TNFRSF1B (TNFR2),TNFRSF1B,TNFR2,7133,Apoptosis,Other immunomodulator,TNFR2 is a TNF receptor superfamily member 1B. It mediates the recruitment of anti-apoptotic proteins.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFR2
TPH1 (TPH1),TPH1,TPH1,7166,Amine-derived hormones,Other immunomodulator,Tryptophan hydroxylase 1 catalyzes the first and rate limiting step in the biosynthesis of serotonin.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TPH1
TTK (TTK),TTK,TTK,7272,Cell Cycle,Targeted by Other Immuno-Oncology Therapy Type,TTK protein kinase is a dual specificity kinase found to be a critical mitotic checkpoint protein for the segregation of chromosomes.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TTK
TYRP1 (TYRP1),TYRP1,TYRP1,7306,Metabolism of amino acids and derivatives,Targeted by Other Immuno-Oncology Therapy Type,TYRP1 or tyrosinase related protein 1 plays a role in melanin biosynthesis.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TYRP1
TNFSF11 (TNFSF11),TNFSF11,TNFSF11,8600,Cytokine Signaling in Immune system,Other immunomodulator,"TNFSF11 is TNF superfamily member, and shown to be a dendritic cell survival factor and involved in the regulation of T cell-dependent immune response.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFSF11
TNFRSF25 (TNFRSF12),TNFRSF25,TNFRSF12,8718,Cytokine Signaling in Immune system,Other immunomodulator,"TNFRSF12 is TNF receptor superfamily member, and may regulate lymphocyte homeostasis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF12
TNFSF13 (TNFSF13),TNFSF13,TNFSF13,8741,Cytokine Signaling in Immune system,Other immunomodulator,"TNFSF13 is TNF superfamily member, and is important for B cell development.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFSF13
TNFRSF11A (TNFRSF11A),TNFRSF11A,TNFRSF11A,8792,Cytokine Signaling in Immune system,Other immunomodulator,"TNFRSF11A is TNF receptor superfamily member, and regulate the interaction between T cells and dendritic cells.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF11A
TNFRSF10B (TNFRSF10B),TNFRSF10B,TNFRSF10B,8795,Adaptive Immune System,Other immunomodulator,"TNFRSF10B is TNF receptor superfamily member, and transduces apoptosis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF10B
TNFRSF10A (TNFRSF10A),TNFRSF10A,TNFRSF10A,8797,Adaptive Immune System,Other immunomodulator,"TNFRSF10A is TNF receptor superfamily member, and induces apoptosis.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF10A
IL18R1 (IL18R1),IL18R1,IL18R1,8809,Cytokine Signaling in Immune system,Other immunomodulator,Interleukin 18 receptor 1 is induced by IFN-alpha and IL12 in NK and T cells.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL18R1
HDAC3 (HDAC3),HDAC3,HDAC3,8841,Chromatin modifying enzymes,Other immunomodulator,"Histone deacetylase 3 removes the acetyl groups from histones to play a role in transcriptional regulation, cell cycle, and development.",
PDLIM7 (LMP1),PDLIM7,LMP1,9260,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,LMP1 or PDZ and LIM domain 7 functions in protein-protein recognition.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;LMP1
AIM2 (AIM2),AIM2,AIM2,9447,Innate Immune System,Other immunomodulator,AIM2 or absent in melanoma 2 is downstream of IFN-gamma and may control cell proliferation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;AIM2
IL27RA (IL27R),IL27RA,IL27R,9466,Cytokine Signaling in Immune system,Other immunomodulator,IL27R or interleukin 27 receptor subunit alpha leads to transcriptional activation of STAT1 and augments the induction of T-bet expression during initiation of Th1 cell differentiation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL27R
ISG15 (ISG15),ISG15,ISG15,9636,Cytokine Signaling in Immune system,Targeted by Other Immuno-Oncology Therapy Type,ISG15 or ISG15 ubiquitin-like modifier is a ubiquitin-like protein that may regulate chemotactic activity towards neutrophils.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ISG15
VGLL4 (VGLL4),VGLL4,VGLL4,9686,Transcription Regulation,Targeted by Other Immuno-Oncology Therapy Type,VGLL4 or vestigial like family member 4 is a transcriptional cofactor that interacts with TEA domain transcription factors and lower expression correlates with poor survival in solid cancers.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;VGLL4
HDAC6 (HDAC6),HDAC6,HDAC6,10013,Adaptive Immune System,Other immunomodulator,"Histone deacetylase 6 removes the acetyl groups from histones to play a role in transcriptional regulation, cell cycle, and development.",
KLRG1 (KLRG1),KLRG1,KLRG1,10219,Adaptive Immune System,Other immunomodulator,KLRG1 or killer cell lectin like receptor G1 is preferentially expressed on NK cells and may be regulated by MHC class I molecules.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;KLRG1
TRAIP (TRAIP),TRAIP,TRAIP,10293,Adaptive Immune System,Targeted by Other Immuno-Oncology Therapy Type,TRAIP or TRAF interacting protein negatively regulates innate immune signaling by inhibiting TRAF2 activation of NFKB signaling.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TRAIP
TNFSF13B (TNFSF13B),TNFSF13B,TNFSF13B,10673,Cytokine Signaling in Immune system,Other immunomodulator,TNFSF13B or TNF superfamily member 13b is a TNF superfamily member and acts as a B cell activator.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFSF13B
DLL3 (DLL3),DLL3,DLL3,10683,Notch Signaling,Targeted by Other Immuno-Oncology Therapy Type,DLL3 or delta like canonical Notch ligand 3 is a Notch ligand being targeted in lung cancer.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;DLL3
HPSE (HPSE),HPSE,HPSE,10855,Glycosaminoglycan metabolism,Other immunomodulator,HPSE or heparanase cleaves heparan sulfate proteoglycans to permit cell movement through extracellular matrix.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;HPSE
CHEK2 (CHEK2),CHEK2,CHEK2,11200,Cell Cycle,Other immunomodulator,CHEK2 or checkpoint kinase 2 halts cell cycle progression in response to DNA damage and replication blocks.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CHEK2
DKK1 (DKK1),DKK1,DKK1,22943,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,DKK1 or dickkopf WNT signaling pathway inhibitor 1 is a negative regulator of the Wnt pathway and plays a role in development.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;DKK1
BRD4 (BRD4),BRD4,BRD4,23476,Chromatin regulation,T-cell targeted immunomodulator,BRD4 or bromodomain containing 4 associates with the chromosomes during mitosis.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;BRD4
SIGLEC9 (SIGLEC9),SIGLEC9,SIGLEC9,27180,Adaptive Immune System,T-cell targeted immunomodulator,SIGLEC9 or sialic acid binding Ig like lectin 9 has been found to be overexpressed in CD8 T cells in melanoma and may be suppress T-cell function.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;SIGLEC9
CLEC2D (CLEC2D),CLEC2D,CLEC2D,29121,Adaptive Immune System,Other immunomodulator,CLEC2D or C-type lectin domain family 2 member D is a member of the natural killer cell receptor C-type lectin family.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;CLEC2D
IL19 (IL19),IL19,IL19,29949,Cytokine Signaling in Immune system,Other immunomodulator,"IL19 or interleukin 19 belongs to the IL10 cytokine subfamily, and is preferentially expressed on monocytes.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;IL19
TNFRSF12A (TNFRSF12A),TNFRSF12A,TNFRSF12A,51330,Cytokine Signaling in Immune system,Other immunomodulator,"TNFRSF12A or TNF receptor superfamily member 12A is a TNF receptor superfamily member with roles in apoptosis, angiogenesis, cell adhesion and innate immune system.",https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;TNFRSF12A
PCDH18 (PCDH18),PCDH18,PCDH18,54510,Cell adhesion,Other immunomodulator,PCDH18 or protocadherin 18 is a protocadherin thought to play a role in cell-specific connections in the brain.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;PCDH18
RNF43 (RNF43),RNF43,RNF43,54894,Signal Transduction,Targeted by Other Immuno-Oncology Therapy Type,RNF43 or ring finger protein 43 is a RING-type E3 ubiquitin ligase and is thought to negatively regulate Wnt signaling.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2017;Target;RNF43
GPRC5D (GPRC5D),GPRC5D,GPRC5D,55507,GPCRs,Targeted by Other Immuno-Oncology Therapy Type,GPRC5D or G protein-coupled receptor class C group 5 member D is a GPCR that has been a target for CAR T cells for multiple myeloma.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;GPRC5D
HDAC8 (HDAC8),HDAC8,HDAC8,55869,Cell Cycle,Other immunomodulator,"Histone deacetylase 8 removes the acetyl groups from histones to play a role in transcriptional regulation, cell cycle, and development.",
PVRL4 (NECTIN4),PVRL4,NECTIN4,81607,Adherens junctions interactions,Targeted by Other Immuno-Oncology Therapy Type,NECTIN4 or nectin cell adhesion molecule 4 is involved in cell adhesion.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;NECTIN4
MOSPD2 (MOSPD2),MOSPD2,MOSPD2,158747,Innate Immune System,Targeted by Other Immuno-Oncology Therapy Type,MOSPD2 or motile sperm domain containing 2 promotes migration of primary monocytes and neutrophils in response to chemokines.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;MOSPD2
SIGLEC15 (SIGLEC15),SIGLEC15,SIGLEC15,284266,Innate Immune System,Other immunomodulator,SIGLEC15 or sialic acid binding Ig like lectin 15 binds sialylated glycoproteins and plays a role in the innate immune system.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;SIGLEC15
ILDR2 (ILDR2),ILDR2,ILDR2,387597,T-cell activation,T-cell targeted immunomodulator,ILDR2 negatively regulates Notch signaling and T-cell activation.,https://www.cancerresearch.org/scientists/immuno-oncology-landscape?2019-09NRDDACarticle=2019;Target;ILDR2
